No price history available.
Key financial summary
Financials in SAR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | SARm | 652 | 699 | 714 | 799 | 877 | 877 | N/A | N/A |
| Operating profit | SARm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | SARm | 75 | 78 | 18 | 40 | 25 | 28 | N/A | N/A |
| EPS reported | SAR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | SAR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | SAR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | SAR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | SARm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | SARm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | SARm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | SAR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | SAR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in SAR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Scientific & Medical Equipment House engages in the maintenance and repair for medical devices, equipment and supplies. Its services include manpower, subcontractors for maintenance of specialized systems, spare parts and consumables supply, maintenance & catering. The company was founded by Saud bin Muhammad bin Nasser Al-Arifi on November 19, 1979 and is headquartered in Riyadh, Saudi Arabia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Scientific and Medical Equipment House (4014.SR)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Scientific & Medical Equipment House engages in the maintenance and repair for medical devices, equipment and supplies. Its services include manpower, subcontractors for maintenance of specialized systems, spare parts and consumables supply, maintenance & catering. The company was founded by Saud bin Muhammad bin Nasser Al-Arifi on November 19, 1979 and is headquartered in Riyadh, Saudi Arabia.